Harbor Health Care ETF (MEDI) has seen unusual trading volume, which is 25× higher than its average daily volume.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The ETF is heavily concentrated in Eli Lilly, which has been active on multiple fronts, announcing the $202 million acquisition of DNA-focused Engage Biologics, reporting completion of a Phase 1 drug-interaction study for its KRAS-targeting cancer drug olomorasib, and drawing attention after ethics disclosures showed President Trump bought LLY shares around key weight-loss drug milestones. Other major holdings with fresh catalysts include Ascendis Pharma, which continues to enjoy a Strong Buy analyst consensus after strong revenue and profit growth, and Intuitive Surgical, whose upbeat Q1 results highlighted 23% revenue growth, expanding margins, and robust global adoption of its da Vinci 5 and Ion platforms despite regional and cost headwinds. Additional news-driven positions include Rhythm Pharmaceuticals, AbbVie, Abivax, Insmed, and UnitedHealth, where recent analyst upgrades, trial updates, and earnings commentary underscore a mix of pipeline progress, strong launches, and ongoing regulatory and pricing risks across the portfolio.